Invitrogen Introduces Next Generation of Transfection Reagents; Lipofectamine(TM) LTX Reagent Improves DNA Delivery and Lowers Toxicity - siRNA

Invitrogen Introduces Next Generation of Transfection Reagents; Lipofectamine(TM) LTX Reagent Improves DNA Delivery and Lowers Toxicity
August 30, 2006
Invitrogen
CARLSBAD, Calif.--(BUSINESS WIRE)--Aug. 30, 2006--Invitrogen Corporation (Nasdaq:IVGN), a provider of essential technologies for disease research and drug discovery, today introduced a key new product into its successful line of transfection reagents. Lipofectamine(TM) LTX, carrying on the tradition of one of the company's best-selling technologies - Lipofectamine(TM) 2000 - provides highly effective delivery of DNA into a wide range of cell types and a significantly lower toxicity profile.
Lipofectamine(TM) LTX Reagent effectively delivers DNA into the cell, the first critical step in characterizing gene function, and demonstrates high levels of transfection efficiency and protein expression with more than 90 percent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types. Understanding gene function, in turn, helps researchers learn about the molecular basis of disease formation and develop potential therapeutic strategies to combat disease.
The introduction of Lipofectamine(TM) LTX complements Invitrogen's release earlier this year of another member of the Lipofectamine(TM) product line. Lipofectamine(TM) RNAi MAX is a RNAi-specific transfection reagent that offers high transfection efficiency and low toxicity profiles on a wide variety of cell types for siRNA gene knockdown experiments.
"These technologies add significant capabilities to a transfection portfolio that is already widely adopted throughout the industry and was instrumental in establishing applications such as RNAi and stem cell research," said Claude Benchimol, Ph.D., Senior Vice President of Research and Development for Invitrogen.
"Our commitment to continual improvement in our core technologies is demonstrated in the release of Lipofectamine(TM) LTX and Lipofectamine(TM) RNAi MAX," concluded Mark Gardner, Invitrogen's Vice President of Molecular Biology Essentials. "Lipofectamine(TM) 2000 is one of our company's top products, and with the advances these new reagents provide, we have a chance to support new and rapidly expanding research applications with the next generation of gene delivery solutions."
For more information, please visit www.invitrogen.com/transfection.